Skip to main content
Home
Latest news
Browse topics
Lupus Rheumatoid arthritis Spondyloarthropathies COVID-19 Browse all topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA Anifrolumab for the treatment of SLE JAK inhibitor safety: Weighing up the data and understanding the risks Rituximab and rheumatology practice in the COVID-19 era Safety snapshot: Upadacitinib in patients with PsA Repurposing rheumatology drugs for COVID-19 Telemedicine in rheumatology: COVID-19 and beyond Managing PsA in resource-limited settings
Conferences
ACR Convergence 2022 EULAR 2022 Congress
About us
Medicine Matters Rheumatology
EXTENDED SEARCH

24-10-2018 | Systemic lupus erythematosus | ACR/ARHP 2018 | Video

Ustekinumab shows potential for the treatment of SLE

Ronald van Vollenhoven discusses phase II trial results demonstrating that the interkeukin-12/23 inhibitor ustekinumab may be a promising treatment option for systemic lupus erythematosus (5:36).

Related content

10-11-2017 | Systemic lupus erythematosus | ACR/ARHP 2017 | News

Further development of ustekinumab supported in SLE

20-06-2019 | Systemic lupus erythematosus | Highlight | Article

Systemic lupus erythematosus: Novel therapies and targeted treatments

28-09-2018 | Axial spondyloarthritis | News

Ustekinumab disappoints in axSpA

31-10-2018 | Psoriatic arthritis | ACR/ARHP 2018 | News

Post-hoc analysis supports further investigation of ustekinumab in PsA-associated spondylitis
Image Credits